Hemophilia B or Christmas disease is an X-linked recessive bleeding disorder with a prevalence of ~1 in 30,000 males worldwide that is clearly less common than hemophilia A. Patients with hemophilia B suffer from recurrent joint bleeds, ecchymosis, epistaxis, and post-dental extraction bleeding. Nevertheless women who are carriers of this abnormality are asymptomatic. Timely diagnosis of disorder is made based on family history, clinical manifestations, and appropriate laboratory studies. Replacement therapies with intravenous injection of plasma-derived factor IX (FIX) and recombinant FIX (rFIX) are current therapeutic choices that have significantly improved life expectancy and quality of life in these patients; but inhibitor formation occurring in ~1% of patients remains as a challenge of replacement therapy that can cause infused FIX concentrate to be less efficient. Gene therapy is the only definitive curative option, but some time will pass before it becomes available as a routine treatment choice.
KeywordsHemophilia B Factor IX deficiency Factor IX Christmas disease Gene therapy
We appreciate Professor Edward Tuddenham for his valuable comments that significantly improved the quality of this chapter.
- 2.DeLoughery TG. Basics of coagulation. In: Hemostasis and thrombosis. Cham: Springer; 2015. p. 1–7.Google Scholar
- 16.Jedidi I, et al. Acquired haemophilia B: a case report and literature review. Ann Biol Clin. 2011;69:685–8.Google Scholar
- 24.Kitchen S, McCraw A, Echenagucia M. Diagnosis of hemophilia and other bleeding disorders. A laboratory manual. Montreal: World Federation of Hemophilia; 2000.Google Scholar
- 31.Elm T, Oestergaard H, Tranholm M. Dose response and prolonged effect of 40K PEG-FIX on bleeding in hemophilia B mice. J Thromb Haemost. 2009;7:134.Google Scholar